Triclabendazole treatment in experimental goat fasciolosis: anthelmintic efficacy and influence in antibody response and pathophysiology of the disease.
A controlled test of the efficacy of triclabendazole against all stages (early immature, late immature and mature) of Fasciola hepatica has been performed in experimentally infected goats. The influence of triclabendazole treatment on the pathophysiology of the disease, in terms of haematological parameters and serum enzyme levels, and in the dynamics of production of specific antibodies to excretory/secretory products (ESP) of F. hepatica were also examined. Goats were orally infected with 200 viable metacercarie and treated at 4, 8 and 16 weeks postinfection (PI) with triclabendazole at the dose rate of 10 mg kg-1 body weight. The drug can be regarded as highly effective against mature (100%) and late immature (99.2%) flukes and effective against early immature flukes (94.9%). A moderate anaemia was found associated with the presence of late immature and mature flukes in bile ducts. Treatment with triclabendazole, by eliminating most of these flukes, largely reduced haematological alterations. Serum levels of the enzymes aspartate aminotransferase, lactate dehydrogenase and gamma-glutathione transferase reflected hepatic damage during goat fasciolosis. Early treatment (at 4 weeks PI) prevents the development of both parenchyma and bile ducts lesions; treatment at 8 weeks PI only prevents bile ducts lesions and treatment at 16 weeks PI has no appreciable effect on the development of the main hepatic lesions. The antibody response to F. hepatica ESP, as measured by enzyme-linked immunosorbent assay, was also affected by treatment with triclabendazole. In all treated animals a peak in antibody levels was observed between weeks 9 and 13, followed by a drop whose magnitude depended on the efficacy of treatment. In those animals in which triclabendazole was highly effective, antibody levels fell back to negative values similar to those recorded preinoculation at 18-21 weeks PI.
Martínez-Moreno
A
A
Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad de Córdoba, Spain.
Jiménez
V
V
Martínez-Cruz
M S
MS
Martínez-Moreno
F J
FJ
Becerra
C
C
Hernández
S
S
D000704:Analysis of Variance; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D000909:Antibodies, Helminth / Q000096:biosynthesis* / Q000097:blood; D000917:Antibody Formation; D001219:Aspartate Aminotransferases / Q000097:blood; D001562:Benzimidazoles / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D004906:Erythrocyte Count; D005210:Fasciola hepatica / Q000276:immunology*; D005211:Fascioliasis / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D015511:Goat Diseases; D006041:Goats; D006454:Hemoglobins / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D012709:Serum Albumin / Q000032:analysis; D013997:Time Factors; D000077682:Triclabendazole; D005723:gamma-Glutamyltransferase / Q000097:blood
D000871:Anthelmintics; D000909:Antibodies, Helminth; D001562:Benzimidazoles; D006454:Hemoglobins; D012709:Serum Albumin; D000077682:Triclabendazole; D007770:L-Lactate Dehydrogenase; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases